Visterra Inc.’s $8.1 million in proceeds from its upsized Series A round gives the company enough cash to finish Phase I trials with its influenza drug and choose a lead candidate for advancement against dengue fever.
While patents continue to clog the U.S. biosimilar pipeline, other countries are benefiting from an increasing flow of the discounted copies of complex biologics.
Amylon LLC, a spinout of Aphios Corp., is prepared to tilt at the windmill that is Alzheimer’s disease through a chemical pathway that has defeated numerous previous attempts, including drugs from industry giant Eli Lilly and Co.
The capital markets cooled off somewhat in November with the Nasdaq and Dow Jones Industrial averages both finishing with small gains of 2.5 percent and 3.4 percent, respectively. The uncertain market conditions were also enough to halt the initial public offering (IPO) aspirations of several biotech companies who pulled their IPOs this month. Those included Celladon Corp., of San Diego, which has a heart failure compound Mydicar in Phase II trials; Globeimmune Inc., of Louisville, Colo.; Tetralogic Pharmaceuticals Inc., of Malvern, Pa.; and Vital Therapies Inc., of San Diego.
The capital markets cooled off somewhat in November with the Nasdaq and Dow Jones Industrial averages both finishing with small gains of 2.5 percent and 3.4 percent, respectively. The uncertain market conditions were also enough to halt the initial public offering (IPO) aspirations of several biotech companies who pulled their IPOs this month. Those included Celladon Corp., of San Diego, which has a heart failure compound Mydicar in Phase II trials; Globeimmune Inc., of Louisville, Colo.; Tetralogic Pharmaceuticals Inc., of Malvern, Pa.; and Vital Therapies Inc., of San Diego.
• Bioxodes SA, of Marche-en-Famenne, Belgium, completed a €2.6 million (US$3.5 million) first seed funding round with a consortium of angel investors and Belgian investment funds.
• Evoke Pharma Inc., of San Diego, selected Synteracthcr Inc. to serve as its primary contract research organization for its upcoming Phase III trial with EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
• Kineta Inc., of Seattle, said it enrolled the first subject in a Phase Ib trial of lead candidate ShK-186, an immune-sparing therapeutic in development for a variety of autoimmune indications.
RSS